Screening Models for Early Detection of Late-onset Preeclampsia With Various Markers in Low-risk Pregnancy Populations
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Preeclampsia
- Sponsor
- CHA University
- Enrollment
- 262
- Primary Endpoint
- identification of patients at risk for late-onset preeclampsia with sFlt-1/PlGF ratio
- Status
- Completed
- Last Updated
- 13 years ago
Overview
Brief Summary
For the prediction of late-onset preeclampsia (PE) in low risk women, the investigators established a cut-off value for sFlt-1/PlGF ratio and evaluated the combination models of Elecys, second trimester uterine artery (UtA) doppler, and fetoplacental proteins for Down syndrome screening.
Detailed Description
A prospective study was carried on in Cha hospital. Serum samples for Down syndrome screening were assayed to estimate pregnancy-associated plasma protein-A (PAPP-A), alpha-fetoprotein , unconjugated estriol, human chorionic gonadotrophin , and inhibin-A. Women screened for Down syndrome were offered UtA Doppler at 20-24 weeks of gestation and then collected serial serum samples for sFlt-1/PlGF ratio at two time points (24-27 and 34-37 weeks' gestation).
Investigators
Dong Hyun Cha
professor
CHA University
Eligibility Criteria
Inclusion Criteria
- •Women considered as a potential participant in this research were patients regularly visited at the prenatal care of Cha hospital in Seoul, Korea
Exclusion Criteria
- •early onset and cases not to measure the sFlt/PlGF ratio and other markers
- •twin pregnancy
- •Chronic hypertension
- •prior history of preeclampsia
- •pregestational diabetes mellitus
- •gestational diabetes mellitus
- •patients delivered before 35 weeks of gestation
- •preeclamptic patients with onset before 35 weeks of gestation
- •patients with body mass index 25kg/m2 or greater
- •maternal age 40 years older
Outcomes
Primary Outcomes
identification of patients at risk for late-onset preeclampsia with sFlt-1/PlGF ratio
Time Frame: at delivery
Secondary Outcomes
- identification of patients at risk for late-onset preeclampsia with combined biochemical markers(at delivery)